Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety

Digestion

Volumn 60, Issue SUPPL. 3, 1999, Pages 1-16

  Scarpignato, Carmelo ^a   Pelosini, Iva ^b  

^a Maggiore University Hospital   (Italy)

^b NONE

Author keywords

Acute pancreatitis; Lanreotide; Octreotide; Pancreatic fistula; Pancreatic surgery; Somatostatin; Upper GI bleeding; Vapreotide; Variceal bleeding

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTICLE; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LOWER ESOPHAGUS SPHINCTER PRESSURE; LUNG EDEMA; NAUSEA; OUTPATIENT CARE; PANCREAS SURGERY; PARALYTIC ILEUS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0032698231     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051484     Document Type: Article

References (135)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
2. Bloom SR, Polak JM: Somatostatin. Br Med J 1987;295:288-290.
3. Holt RIG, McGregor AMM: Somatostatin: from Basic Science to Clinical Application. Excerpta Medica Asia. Hong Hong, 1996, pp 1-146.
4. Jenkins SA: Emerging Differencies in the Therapeutic Efficacy of Somatostatin and Octreotide in Gastroenterology and Surgery. Medi-Media Asia. Hong Hong, 1996, pp 1-160.
5. Scarpignato C (ed): Octreotide: from Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 1-312.
6. Guillemin R: Somatostatin: the early days. Metabolism 1993;41(suppl 2):1-4.
7. Reichlin S: Somatostatin. Part One. New Engl J Med 1983;309:1495-1501.
8. Reichlin S: Somatostatin. Part Two. New Engl J Med 1983;309:1556-1563.
9. Polak JM, Bloom SR: Somatostatin localization in tissues. Scand J Gastroenterol 1986;21 (supp 119):11-21.
10. Bordi C, D'Adda T, Azzoni C, Ferraro G: The somatostatin cell. In: Scarpignato C (ed): Octreotide: from Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 2-22.
11. Schusdziarra V: Somatostatin: biological actions and pathophysiology. In: Scarpignato C (ed): Octreotide: from Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 35-53.
12. Scarpignato C, Pelosini I: Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999;13(suppl A):50A-65A.
13. Debas HT: Somatostatin: physiological and clinical potential. Gastroenterol Int 1989;2: 185-189.
14. Pless J, Bauer W, Briner U, Doepner W, Marbach P, Maurer R, Petcher TJ, Reubi J-C, Vonderscher J. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 1986;21(suppl 119):54-64.
15. Ho LT, Chen RL, Chou TY, Fong JC, Wong PS, Chou CK: Pharmacokinetics and effects of intravensous infusion of somatostatin in normal subjects - a two-compartment open model. Clin Physiol Biochem 1986;4:257-267.
16. Marks N, Stern F: Inactivation of somatostatin (GH-RIH) and its analogs by crude and partially purified rat brain extracts. FEBS Lett 1975; 55:220-224.
17. Pless J: Chemical structure - Pharmacological profile of Sandostatin®. In: O'Dorisio TM (ed): Sandostatin in the Treatment of GEP Endocrine Tumors. Springer Verlag, Berlin, 1989, pp 3-13.
18. Vale W, Rivier J, Ling N, Brown M: Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978;27 (suppl 1):1391-1401.
19. Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38:658-702.
20. Camboni MG: Octreotide. In: Braga PC, Guslandi M, Tittobello A (eds): Drugs in Gastroenterology. Raven Press, New York, 1991, 318-336.
21. Scarpignato C: Octreotide, the synthetic long-acting somatostatin analogue: pharmacological profile. In: Scarpignato C (ed): Octreotide. From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 54-72.
22. Eriksson B, Tiensuu Janson E, Bax NDS, Mignon M, Morant R, Opolon P, Rougier P, Oberg KE: The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 1996;57 (suppl 1): 77-80.
23. Lamrani A, Vidon N, Sogni P, Nepveux P, Catus F, Blumberg J, Chaussade S: Effects of lanreotide, a somatostatin analogue, on post-prandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997;43:65-70.
24. Barthomeuf C, Pourrat H, Pourrat A, Ibrahim H, Cottier PE: Stabilization of Octastatin registered, a somatostatin analogue: Comparative accelerated stability studies of two formulations for freeze-dried products. Pharm Acta Helv 1996;71:161-166.
25. Veber DF, Freidlinger RM, Perlow DS, Paleveda WJ, Holly FW, Strachan RG, Nutt RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R: A potent cyclic hexapeptide analogue of somatostatin. Nature 1981;292:55-58.
26. Beglinger C, Drewe J: Somatostatin and octreotide: physiological background and pharmacological application. Digestion 1999;60(suppl 2):2-8.
27. Lewin MJM, Le Romancer M: Somatostatin receptors. In: Scarpignato C (ed): Octreotide. From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 23-34.
28. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
29. Patel YC, Srinkant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR 1-5). Endocrinology 1994;135:2814-2817.
30. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB: The somatostatin receptor family. Life Sci 1995;57: 1249-1265.
31. Reubi JC: Octreotide and nonendocrine tumors: basic knowledge and therapeutic potential. In: Scarpignato C (ed): Octreotide. From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 246-269.
32. Reubi JC, Landolt AM: High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocr Metab 1984;59:1148-1151.
33. Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H: Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocr Metab 1986;62:729-733.
34. De Franchis R, Primigiani R: Why do varices bleed? Gastroenterol Clin North Am 1992;21: 65-101.
35. Polio J, Groszmann RJ: Hemodynamic factors involved in the development and rupture of esophageal varices: A pathophysiologic approach to treatment. Semin Liver Dis 1986;6: 318-331.
36. Escorsell A, Bosch J: Pathogenesis of bleeding in portal hypertension. Digestion 1998;59:2-5.
37. Bosch J, Groszmann RJ: Measurement of the azygos venous blood flow by continuous thermodilution technique. An index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 1984;4:424-429.
38. Bosch J: Effect of pharmacological agents on portal hypertension. A haemodynamic appraisal. Clin Gastroenterol 1985;1:169-184.
39. Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J: Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 1986;4:309-317.
40. Lebrec D: Drugs for portal hypertension. J Gastroenterol Hepatol 1987;2:361-374.
41. Barbare JC, Poupon R, Jaillon P, Bories P, Aussanaire M, Darnis F, Michel H, Cheymol G: The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: A study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Hepatology 1984;4: 59-62.
42. Scarpignato C: Clinical pharmacology of active variceal bleeding. Dig Dis 1992;10(suppl 1): 16-29.
43. Imperiale TF, Teran JC, McCullogh AJ: A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrage. Gastroenterology 1995;109: 1289-1294.
44. D'Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-354.
45. Ferayorni L, Polio J, Grozsmann RJ: Drug therapy for portal hypertension: a 5-year review; in De Franchis R (ed): Portal Hypertension II. Blackwell Science, Oxford, 1996, pp 68-97.
46. Mottet C, Sieber CC, Nauer A, Drewe J, Fried R, Larsen F, Beglinger C: Hemodynamic effects of the somatostatin analog lanreotide in humans: Placebo-controlled, cross-over dose-ranging echo-doppler study. Hepatology 1998; 27:920-925.
47. Wahren J, Felig G: Influence of somatostatin on carbohydrate disposal and absortion in diabetes mellitus. Lancet 1976;ii:1213-1216.
48. Sonnenberg GE, Keller U, Perruchoud A, Burckhardt D, Gyr K: Effect of somatostatin on splanchnic haemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981;80:526-532.
49. Tyden G, Samnegaard H, Thulin L, Muhrbeck O, Efendic S: Circulatory effects of somatostatin in anaesthetized man. Acta Chir Scand 1979;145:443-446.
50. Merkel C, Gatta A, Zuin R, Finucci GF, Arnaboldi L, Roul A: Effect of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985;32:92-98.
51. Bosch J, Kravetz D, Rodes J: Effects of somatostatin on hepatic and systemic haemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology 1981;80:518-525.
52. Bories P, Pomler-Layrargues G, Chotard JP, Jacob C, Michel H: Somatostatin reduces portal hypertension in cirrhotic patients. Gastroenterol Clin Biol 1980;4:616-617.
53. Eriksson LS, Law DH, Wahren J: Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis. Clin Physiol 1984; 4:5-11.
54. Mastai R, Bosch J, Navasa M, Silva G, Kravetz D, Bruix J, Viola C, Rodes J: Effects of continuous infusion and bolus injections of somatostatin on azygous blood flow and hepatic and systemic haemodynamics in patients with portal hypertension: Comparison with vasopressin. J Hepatol 1986;3(suppl 1):53A.
55. Sonnenberg A, West C: Somatostatin reduced gastric mucosal flow in normal subjects but not in patients with cirrhosis of the liver. Gut 1983; 24:148-153.
56. Kleber G, Sauerbruch T, Fischer G, Paumgartner G: Somatostatin does not reduce oesophageal variceal pressure in liver cirrhosis. Gut 1988;29:153-156.
57. Cirera I, Feu F, Luca A, Garcia-Pagán JC, Fernandez M, Escorsell A, Bosch J, Rodes J: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind haemodynamic investigation. Hepatology 1995;22:106-111.
58. Jenkins SA, Baxter JN, Snowden S: The effects of somatostatin and SMS 201-995 on hepatic and systemic haemodynamics in patients with cirrhosis and portal hypertension. Fibrinolysis 1988;2:48-50.
59. McKee RK, Pringle SD, Garden OJ, Lorimer AR, Carter DC: SMS 201-995 in the management of variceal bleeding. Gut 1989;28: A1380.
60. Jenkins SA, Baxter JN, Corbett WA, Shields R: Effects of somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985; 72:1009-1012.
61. Navasa M, Bosch J, Chesta J, Bru C, Pizcueta P, Garcia-Pagán JC, Betz C, Casamitjana R, Rodés J: Haemodynamic effects of subcutaneous administration of SMS 201-995, a long-acting somatostatin analogue, in patients with cirrhosis and portal hypertension. J Hepatol 1988;7:123.
62. Primignani M, Carpinelli L, Vazzoler MC, De Lima MCH, Nolte A, Marcelli R, De Franchis R: Short-term effect of octreotide on intraoesophageal pressure: a double blind placebo-controlled study. Eur J Gastroenterol Hepatol 1994;6:1027-1031.
63. McCormick PA, Chin J, Greenslande L, Karatapanis S, Dick R, McIntyre N, Burroughs AK: Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995;21: 1255-1260.
64. Jenkins SA, Nott DM, Baxter N: Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension: relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. HPB Surgery 1998;11:13-21.
65. McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagsta VD, McIntyre N, Burroughs AK: Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study. Hepatology 1992;16:1180-1186.
66. Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, Escartin P: Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
67. Lin HC, Tsai YT, Huang CC, Meng HC, Lee FY, Wang SS, Lee SD, Lo KJ: Effects of octreotide on postprandial systemic and hepatic hemo-dynamics in patients with postnecrotic cirrhosis. J Hepatol 1994;21:424-429.
68. Buonamico P, Sabba C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen JE, Lerner E, Taylors KJW, Albano O, Grozmann RJ: Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology 1995;21:134-139.
69. Garcia-Pagan JC, Feu F, Castells A, Luca A, Hermida RC, Rivera F, Bosch J, Rodes J: Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994;19:595-601.
70. Merican I, Sprengers D, McCormick PA, Minoli G, McIntyre N, Burroughs AK: Diurnal pattern of variceal bleeding in cirrhotic patient. J Hepatol 1993;19:15-22.
71. Burroughs AK: Somatostatin and octreotide for variceal bleeding. J Hepatol 1991;13:1-4.
72. LiCalzi LK, Biancani P, Behar J, Kerstein MD: Effect of hemorrhagic hypotension and hypoventilation on lower esophageal sphincter pressure. Ann Surg 1980;192:53-57.
73. Caldwell MPT, Marks P, Byrne PJ, Walsh TN, Hennesy TP: Hypotension induced by haemorrhage impairs lower oesophageal sphincter function. Br J Surg 1994;81:1517-1519.
74. Miskowiak J: How the lower oesophageal sphincter affects submucosal oesophageal varices. Lancet 1978;ii:1284-1285.
75. Miskowiak J, Burcharth F, Jensen L: Effect of lower ocsophageal sphincter on oesophageal varices. A portographic study. Scand J Gastroenterol 1981;16:957-960.
76. Mastai R, Grande L, Bosch J, Bruix J, Rigau J, Kravetz D, Navasa M, Pera C, Rodés J: Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. Hepatology 1986;6: 1244-1247.
77. Greco AV, Bianco A, Altamonte L, D'Acquarica L, Ghirlanda G: Effect of somatostatin on lower esophageal sphincter (LES) pressure and serum gastrin in normal and achalasic subjects. Horm Metab Res 1982;14:26-28.
78. Gunshefski LA, Rifley WJ, Slattery DW, Schifini JJ, Hartsuck M, Little AG: Somatostatin stimulation of the normal esophagus. Am J Surg 1992;163:59-62.
79. Barrioz T, Borderie C, Strock P, Ingrand P, Fort E, Silvain C, Bcauchant M: Effects of octreotide on lower esophageal sphincter in patients with cirrhosis and portal hypertension. Dig Dis Sci 1998;43:1566-1571.
80. Whitehouse I, Beglinger C, Fried M, Gyr K: The effect of an octapeptide somatostatin analogue (SMS 201-995) and of somatostatin-14 [SST-14] on pentagastrin-stimulated gastric acid secretion: a comparative study in man. Hepatogastroenterol 1984;31:227-229.
81. Christiansen J, Yotis A: The role of somatostatin and a long-acting analogue. SMS-201, 995, in acute bleeding due to peptic ulceration. Scand J Gastroenterol 1986;21(suppl 119): 109-114.
82. Bloom SR, Mortimer CH, Thorner MO, Besser GM, Hall R, Gomez-Pan A, Roy VM, Russel RC, Coy DH, Kastin AJ, Schally AV: Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974;2:1106-1109.
83. Schrumpf E, Vatn MH, Hanssen KF, Myren J: A small dose of somatostatin inhibits the pentagastrin stimulated gastric secretion of acid, pepsin and intrinsic factor in man. Clin Endocrinol 1978;8:391-395.
84. Green FV, Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin on blood coagulation and platelet aggregation. Gastroenterology 1978;74:38-43.
85. Gazzaniga PP, Di Macco G, La Mancusa R, Oddi A, Pappalardo G, Pulcinelli FM, Reggio D: In vitro enhancement of human platelet aggregation by somatostatin. Experientia 1988; 44:892-894.
86. Baxter JN, Jenkins SA, Day DW, Shields R: Effects of a somatostatin analogue (SMS 201-995) on hepatic and splenic reticuloendothelial function in rat. Br J Surg 1985;72:1005-1008.
87. Kutz K, Nuesch E, Rosenthaler J: Pharmacokinetics of SMS 201-995 in healthy subjects. Scan J Gastroenterology 1986;21(suppl 119):65-72.
88. Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F: The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997; 26:1018-1025.
89. Swain CP, Storey DW, Bown SG, Heath J, Mills TN, Salmon PR, Northfield TC, Kirkham J, O'Sullivan JP: Nature of the bleeding vessel in recurrently bleeding gastric ulcers. Gastroenterology 1986;90:595-608.
90. Cook DJ, Guyatt GH, Salena BJ, Laine LA: Endoscopie therapy for acute non-variceal upper gastrointestinal haemorrhage: a meta-analysis. Gastroenterol 1992;102:1.19-148.
91. Imperiale TF, Birgisson S: Somatostatin or octreotide compared with H2-antagonists and placebo in the management of acute non-variceal upper gastrointestinal hemorrage: a meta-analysis. Ann Intern Med 1997;127: 1062-1071.
92. Johansson C, Aly A: Stimulation of gastric mucus output by somatostatin in man. Eur J Clin Invest 1982;12:37-39.
93. Romano M, Razandi M, Ivey KJ: Somatostatin stimulates prostaglandin production by rat gastric epithelial cells in vitro, but is not cytoprotective. Dig Dis Sci 1988;33:1435-1440.
94. Kusterer K, Rohr G, Schwedes U, Usadel KH, Szabo S: Gastric mucosal protection by somatostatin. Klin Wochcnschr 1986;64 (suppl VII): 97-99.
95. Lunde OC, Kvernebo K, Hanssen LE, Larsen S: Effect of somatostatin on human gastric blood flow evaluated by endoscopie laser Doppler flowmetry. Scand J Gastroenterol 1987;2:842-846.
96. Modlin IM, Basson M, Scarpignato C: The management of nonvariceal upper digestive bleeding: is there a role for somatostatin and its analogues? In: Scarpignato C (ed): Octreotide. From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 139-150.
97. Gullo L, Priori P, Scarpignato C, Baldoni F, Mattioli G, Barbara L: Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci 1987;32:1065-1070.
98. Gullo L, Pezzilli R. Barbara L: Effect of somatostatin on plasma aminoacid uptake by human pancreas. Gastroenterology 1989;97: 732-736.
99. Gullo L, Pezzilli R, Ancona D, Labate AM, Barbara L: Effect of octreotide, a long-acting somatostatin analogue, on plasma amino acid uptake by the pancreas. Pancreas 1991;6: 668-672.
100. Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, Büchler MW: Potential role of somatostatin and octreotide in the management of acute pancreatitis. Digestion 1994;55(suppl 1):10-15.
101. Londong W, Angerer M, Kutz K, Landgraf R, Londong V: Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989;96:713-722.
102. Büchler MW, Uhl W, Malfertheiner P (eds): Pankreaserkrankungen: Akute Pankreatitis, Chronische Pankreatitis, Pankreastumore. Karger, Basel, 1996.
103. Glasbrenner B, Adler G: Pathophysiology of acute pancreatitis. Hepato-gastroenterology 1993;40:517-521.
104. Marteu P, Chretien Y, Calmus Y, Parc R, Poupon R: Pharmacological effect of somatostatin on bile secretion in man. Digestion 1989;42:16-21.
105. Andersen HB, Petronijevic L, Giese B, Mygind T, Burcharth F: Somatostatin reduces bile secretion and loss of bile constituents in patients with external biliary drainage. HPB Surg 1996;9:229-233.
106. Demesi E, Corazziari E, Torsoli A: Somatostatin and sphincter of Oddi pressure activity. In: Angelini L, Usadel KH (eds): Therapeutic Effects of Somatostatin. Serono Symposia, Academic Press, New York 1984, pp 69-71.
107. Ahrendt SA, McGuire CH, Lilemoe KD, Trias M, Kaloo A, Pitt HA: Somatostatin inhibits sphincter of Oddi motility. Gastroenterology 1990;98:242A.
108. Binmoeller KF, Dumas R, Harris AG, Delmont JP: Effects of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-777.
109. Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, Shields R: Effects of somatostatin and a long-acting somatostatin analogue in the treatment and prevention of experimentally-induced acute pancreatitis in the rat. Br J Surg 1985;72:382-385.
110. Papp M: Pancreatic cytoprotection: New approaches. Acta Physiol Hung 1992;80:399-406.
111. Paice JA, Kroin JS, Penn RD: Analgesic effect of octreotide: therapeutic potential. In: Scarpignato C (ed): Octreotide: from Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 270-280.
112. Karalis K, Mastorakos G, Chrousos GP, Tolis G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-2006.
113. Matucci-Cerinic M, Borelli F, Generini S, Cantelmo A. Marcucci I, Martelli F, Romagnoli P, Bacci S, Conz A, Marinelli P, Marabini S: Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum 1995;38:1687-1693.
114. Limberg K, Kommerell B: Treatment of acute pancreatitis with somatostatin. N Engl J Med 1980;79:284.
115. Uhl W, Anghelacopoulos SE, Friess H, Büchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion 1999;60(suppl 2):23-30.
116. Carballo F, Dominguez-Munoz JE, Fernandez-Calvet L, Martinez-Pancorbo C, Garcia A, de la Morena J: is somatostatin useful in the treatment of acute pancreatitis? A meta-analysis. Digestion 1991;49:A12-13.
117. Fedorak IJ, Prinz RA: Octreotide in the treatment of pancreatic fistula. In: Scarpignato C (ed): Octreotide: from Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 201-209.
118. Roncoroni L, Violi V, Montanari M, Muri M: Effect of somatostatin on exocrine pancreas evaluated on a total pancreatic fistula of neoplastic origin. Am J Gastroenterol 1983;78: 425-428.
119. Bassi C, Falconi M, Caldiron E, Bonora A, Salvia R, Pederzoli P: Somatostatin analogues and pancreatic fistulas. Digestion 1996;57(suppl 1):94-96.
120. Trede M, Schwall G: The complications of pancreatectomy. Ann Surg 1988;207:39-47.
121. Klempa J, Schwedes U, Usadel KH: Verhütung von postoperativen pankreatischcn Komplikationen nach Duodenopankreatektomie durch Somatostatin. Chirurg 1979;50: 427-432.
122. Berberat PO, Friess H, Uhl W, Büchler MW: The Role of Octreotide in the Prevention of complications following pancreatic resection. Digestion 1999;60(suppl 2): 15-22.
123. Gouillat C, Chipponi J, Partensky C, Baulieux J: Effects of somatostatin infusion on the pancreatic remnant secretions after pancreatoduodenectomy. Hepato-gastroenterology 1989;45(suppl 1):398A.
124. Burroughs AK, Planas R, Svoboda P: Optimizing emergency care of upper gastrointestinal bleeding in patients with cirrhosis. Scand J Gastroenterol 1998;33(suppl 226): 14-24.
125. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL: Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346: 865-868.
126. Steinberg W, Tenner S: Medical progress: Acute pancreatitis. N Engl J Med 1994;330: 1198-1210.
127. Mulvihill S, Pappas TN, Passaro E, Debas HT: The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery 1986;100:467-476.
128. Scarpignato C, Camboni MG: Safety profile of octreotide. In: Scarpignato C (ed): Octreotide. From Basic Science to Clinical Medicine. Karger, Basel, 1996, pp 296-309.
129. Gaudin C, Moreau R, Champigneulle B, Soubrane O, Kleber G, Lebrec D: Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995;15:236-241.
130. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP: Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
131. Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R: A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41: 526-533.
132. Minocha A, Dean HA Jr: Octreotide-induced acute hepatic toxicity. Am J Gastroenterol 1991;81:525-526.
133. Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, Larricq J, Gourlaouen A, Ribard D, Kara NM, Legoux JL, Pillegand B, Becker MC, Di Costanzo J, Metreau JM, Silvain C, Beauchant M: Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333:555-560.
134. Sherwin RS, Hendler R, DeFronzo R, Wahren J, Felic P: Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 1977;74:348-352.
135. Bourne HR, Roberts JM: Drug receptors and pharmacodynamics. In: Katzung BG (ed): Basic and Clinical Pharmacology, Fourth Edition. Appleton & Lange, Norwalk 1989, pp 10-28.